Access cutting-edge membranous nephropathy treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access membranous nephropathy specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related membranous nephropathy treatment provided free
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy. Background: Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life. Primary MN is recog
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Check if you qualify for this membranous nephropathy clinical trial in Birmingham, AL
If you're searching for membranous nephropathy treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced membranous nephropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.